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Abstract: Accurate diagnosis of clinically significant prostate cancer is essential in identifying patients who 
should be offered treatment with curative intent. Modifications to the Gleason grading system in recent 
years show that accurate grading and reporting at needle biopsy can improve identification of clinically 
significant prostate cancers. Extracapsular extension of prostate cancer has been demonstrated to be an 
adverse prognostic factor with greater risk of metastatic spread than organ-confined disease. Tumor volume 
may be an independent prognostic factor and should be considered in conjunction with other factors. Multi-
parametric magnetic resonance imaging (MP-MRI) has become an increasingly important tool in the 
diagnosis and characterization of prostate cancer. MP-MRI allows T2-weighted (T2W) anatomical imaging 
to be combined with functional and physiological assessment. Diffusion-weighted imaging (DWI) has shown 
greater sensitivity, specificity and negative predictive value compared to prostate specific antigen (PSA) 
testing and T2W imaging alone and has a more positive correlation with Gleason score and tumour volume. 
Dynamic gadolinium contrast-enhanced (DCE) imaging can exhibit difficulties in distinguishing prostatitis 
from malignancy in the peripheral zone, and between benign prostatic hyperplasia (BPH) and malignancies 
in the transition zone (TZ). Computer aided diagnosis utilizes software to aid radiologists in detecting and 
diagnosing abnormalities from diagnostic imaging. New techniques of quantitative MRI, such as VERDICT 
MRI use tissue-specific factors to delineate different cellular and microstructural phenotypes, characterizing 
tissue properties with greater detail. Proton MR spectroscopic imaging (MRSI) is a more technically 
challenging imaging modality than DCE and DWI MRI. Over the last decade, choline and prostate-
specific membrane antigen (PSMA) positron emission tomography (PET) have developed as better tools 
for staging than conventional imaging. While hyperpolarized MRI shows promise in improving the imaging 
and differentiation of benign and malignant lesions there is further work required. Accurate reading and 
interpretation of diagnostic investigations is key to accurate identification of abnormal areas requiring biopsy, 
sparing those in whom benign or indolent disease can be managed by non-invasive means. Embracing and 
advancing existing technologies is essential in furthering this process.
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Introduction
Accurate diagnosis of clinically significant prostate cancer 
is essential in identifying patients who should be offered 
treatment with curative intent. Traditionally, the diagnosis 
of prostate cancer has been made solely by transrectal 
ultrasound (TRUS) guided biopsy. This can result in the 
over-diagnosis and subsequent overtreatment of low-
grade prostate cancer, but may also fail to detect clinically 
significant cancers. Multi-parametric magnetic resonance 
imaging (MP-MRI) has become an increasingly important 
tool in the diagnosis and characterization of prostate 
cancer (1). Traditional prostate MRI consisted of only T1-
weighted (T1W) and T2-weighted (T2W) imaging, and 
could only be used for local staging in known prostate 
cancer. MP-MRI allows T2W anatomical imaging to be 
combined with functional and physiological assessment. 
Sequences using diffusion-weighted imaging (DWI) and 
dynamic gadolinium contrast-enhanced (DCE) imaging can 
greatly aid in the detection of clinically significant cancer. 
Accurate reading and interpretation of MP-MRI imaging 
is key to the accurate identification of abnormal areas 
which require biopsy, and those which represent benign or 
indolent disease which might avoid a biopsy. Herein, we 
review the literature on qualitative and quantitative MRI 
parameters which can distinguish between malignant and 
benign disease.
Determining clinically significant prostate 
cancer
Clinically significant prostate cancer is frequently 
categorized according to three main prognostic factors as 
defined by Stamey and Epstein (2,3):
(I) Gleason score 7 or greater (3+4=7 or higher);
(II) Extraprostatic tumor extension (T3a disease or 
greater);
(III) Tumor volume on whole-mount prostatectomy 
>0.5 cm3 (although on biopsy different groups 
use different criteria such as number of biopsies 
positive or percentage cancer involvement or 
millimetres of cancer per core).
This definition is derived from the seminal work of 
Hanahan and Weinberg (4). These lesions exhibit more 
malignant behaviour and are more likely to warrant 
treatment compared to smaller, less aggressive tumours that 
can be inconsequential (5). The parameters used to define 
clinically significant prostate cancer aid in prognostication 
of prostate cancer. However, these parameters are not 
used in isolation for clinical decision making where 
further patient characteristics including comorbidities, 
age, performance status and patient choice will further 
contribute.
Gleason score
The Gleason score for prostate cancer was developed in the 
1960s (6). This scoring system analyzed glandular patterns 
within prostate biopsy samples and assigned 2 grades to any 
malignancy detected, based upon the predominant pattern 
and second-most common pattern. Total scores ranged from 
2–10, and an increased score was associated with increased 
cancer-specific mortality. 
The Gleason grading system was initially revised at the 
2005 International Society of Urological Pathology (ISUP) 
Consensus Conference (7). Importantly, this recommended 
that Gleason grades 2–5 would only be given in rare 
circumstances, effectively making Gleason 6 the lowest 
pathological risk category. Furthermore, it further defined 
the criteria for Gleason pattern 3 and pattern 4. Cribriform 
growth patterns that were included in the original pattern 3 
were largely removed and placed into pattern 4. The further 
ISUP Consensus update in 2014 placed all cribriform 
patterns into Gleason pattern 4. Glomeruloid glands are 
now also graded as pattern 4, as well as ill-defined glands 
with poorly formed glandular lumina (8). 
The main impact of the modified Gleason grading was 
an increase in the reporting of higher Gleason scores (9). 
Studies report improved correlation between needle biopsy 
and Gleason grade, stage at final radical prostatectomy 
specimen and subsequent biochemical recurrence on 
follow-up since the modified system was adopted (10,11). 
Furthermore, reassignment of the classical cribriform 
pattern 3 to pattern 4 has been shown to be valuable 
in predicting biochemical recurrence following radical 
prostatectomy (12). 
In addition to the Gleason score attributed to biopsy 
samples, reporting of percentage of Gleason pattern 
4 within biopsy samples found to be Gleason 7 has 
demonstrated improved stratification regarding risk 
of disease progression. This sub-classification enables 
identification of men with relatively insignificant prostate 
cancer (13). Tertiary high-grade Gleason patterns correlate 
with more aggressive disease and worse prognosis secondary 
to different pathologic stage and biochemical progression. 
The modifications to the Gleason grading in recent years 
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shows that accurate grading and reporting at needle biopsy 
can help to identify clinically significant prostate cancers. 
Where the D’Amico classification failed to differentiate 
between Gleason score 3+4=7 and 4+3=7 there has been 
increasing recognition that the latter demonstrates a 
significantly worse prognosis with greater likelihood of 
progression following therapy (14). Grouping of Gleason 
scores by Pierorazio et al. formulated five grades of prostate 
cancer to stratify patients further according to prognosis 
and identify those with a greater likelihood of requiring 
treatment (10). Epstein et al. subsequently demonstrated 
the five-group grading system with histological parameters 
to result in more accurate risk stratification of lesions with 
the additional benefit of being simpler, especially from the 
patient’s perspective (15). A significant, inverse correlation 
is demonstrated between increasing group grading and 
recurrence-free progression following radical prostatectomy 
or radiotherapy, formulating the grading groups as in Table 1. 
Extraprostatic tumor extension
Extracapsular extension of prostate cancer has been 
demonstrated to be an adverse prognostic factor with 
greater risk of metastatic spread than organ-confined 
disease. Wheeler et al. stated that the likelihood of 
metastatic progression was directly linked to invasion into 
or through the prostatic capsule, with worse progression-
free probabilities in patients whose tumors breached the 
prostatic capsule (16). Furthermore, pT3 disease carries 
a greater risk of positive margins at radical prostatectomy 
with Hull et al. finding significantly different progression-
free probability at 10 years following radical retropubic 
prostatectomy when comparing tumors confined versus 
those not confined to the prostate (17). These factors 
contribute to reduced likelihood of establishing long-term 
cancer control in patients. 
Tumor volume
Another important concept in determining significant 
prostate cancer is tumor volume. Although differences exist 
in whether tumor volume is an independent prognostic 
factor, it can be an important variable to consider in 
conjunction with other factors. Cancer volume has been 
shown to strongly correlate with the percentage of poorly 
differentiated cancer and nodal metastases (18). Currently, 
a cut-off figure of 0.5 cc is commonly used to distinguish 
insignificant from clinically significant cancer (19). Stamey 
et al. evaluated 139 cystoprostatectomy specimens where 
the procedure was undertaken within bladder cancer 
management (20). From the specimens the largest 8% of 
prostate cancers identified ranged in volume from 0.5–6.1 mL 
and within these only 20% patients had clinically 
significant prostate cancer. Other studies have placed 
this at 1.3 cc for pure Gleason 6 cancers. Bostwick et al. 
reviewed 9 studies, and concluded that tumor volume was 
a good positive predictor for several measures of tumor 
progression (21). Tumors measuring 0.5 cc had a 10% risk 
of capsular invasion, those measuring 4 cc had 10% risk of 
seminal vesicle invasion, and tumors measuring 5 cc had a 
10% risk of metastases. 
MRI of the prostate
MRI offers a more accurate modality than TRUS for 
both detection and localization of prostate cancer (22). 
Furthermore, the high resolution and soft tissue contrast 
allows for accurate local staging.
T1W imaging
T1W images have a limited role in evaluation of prostate 
cancer. T1W MRI images are sub-optimal for cancer 
detection as tumors show up as iso-intense to the prostate 
Table 1 Grouped grading system for prostate cancer derived from Epstein et al. [2016]
Grading group Gleason score Histological appearances
1 3+3=6 Individual discrete well-formed glands only
2 3+4=7 Predominantly well-formed glands, lesser component of poorly formed/fused/cribriform glands
3 4+3=7 Predominantly poorly formed/fused/cribriform glands, lesser component of well-formed glands
4 8 Poorly formed/fused/cribriform glands or predominantly well-formed glands, lesser component lacking 
glands or predominantly lacking glands, lesser component of well-formed glands
5 9–10 Lack of gland formation (or with necrosis) +/− poorly formed/fused/cribriform glands
S423Translational Andrology and Urology, Vol 7, Suppl 4 September 2018
  Transl Androl Urol 2018;7(Suppl 4):S420-S435tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
gland. Areas of high water content emit low signal allowing 
for poor differentiation between metastatic and normal 
tissue (23). Hemorrhage will demonstrate hyperintensity on 
T1W images thus comparison may be made with T2-MRI 
when evaluating for post-biopsy hemorrhage (24,25).  
T2W imaging
T2W imaging provides useful delineation of the zonal 
anatomy of the prostate gland, although it lacks the 
diagnostic accuracy to be used in isolation. The peripheral 
zone (PZ) of the prostate appears as an area of high signal 
intensity whereas the central gland has variable signal 
intensity. Prostate cancer in the PZ can appear as an area of 
hypo-intense signal compared to the higher signal depicting 
normal prostatic tissue (Figures 1,2).
This is secondary to the reduced free-water content 
of highly dense tumors and studies have demonstrated 
a positive correlation between the reduction in signal 
intensity and higher Gleason score parameters (26). The 
central zone may be replaced by well-circumscribed 
nodules related to benign prostatic hyperplasia (BPH) or 
interventions undertaken for its management (Figure 3). 
However, T2W imaging alone can be inaccurate, as 
some tumors can be isointense. Furthermore, a low signal 
intensity on T2W is also seen in benign situations such as 
prostatitis, BPH, scarring and post-biopsy hemorrhage, 
which can mimic cancer. For this reason, when utilized 
in staging it is recommended that biopsy and T2 MRI be 
conducted with a minimum interval of 6-week (27). T2W 
MRI lacks the diagnostic accuracy to be used in isolation. 
DWI
DWI assesses the ease with which water molecules move 
around within prostatic interstitial space. Rate of water 
diffusion in prostatic tissue is dependent on stromal density 
and tissue interstitial water, thus DWI reflects changes 
that may be caused by neoplastic growths within the 
organ. Prostate cancer results in increased cellularity, and a 
reduction of the extracellular space, and results in restricted 
diffusion on DWI. 
Figure 1 Capsular irregularity with no clear plane between 
prostate gland and adjacent anterior rectum at left posterior aspect 
of gland. T2 imaging.
Figure 2 Crescent of low T2 signal in anterior horn of left mid 
and basal gland, likely tumour.
Figure 3 Area of high intensity secondary to a TURP defect.
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The strength and duration of the diffusion gradient 
detected are referred to as “b-values” with higher values 
resulting in the production of a higher signal intensity 
(Figure 4A). Calculation of aforementioned b-values 
facilitates the construction of an apparent diffusion 
coefficient (ADC) map that demonstrates tumors as having 
low signal intensity secondary to the increased cell density, 
reduced interstitial fluid and reduced free water when 
compared to normal prostatic tissue such as that in a normal 
gland or in BPH (Figure 4B). 
DWI has shown greater sensitivity, specificity and 
negative predictive value compared to PSA measurements 
and T2W imaging and has a more positive correlation 
with Gleason score and tumor volume (28,29). However, 
there exists an overlap between ADC values obtained in 
malignant and benign tissue especially nearing central and 
transitional zones of the prostate.
DCE imaging
DCE imaging utilizes intravenous gadolinium contrast to 
demonstrate the microvascular properties, angiogenesis and 
resulting perfusion rate in tissues. Serial imaging of wash-
in and wash-out periods enables tumors to be identified and 
correlates with tumor aggression (30). Malignant prostate 
lesions have increased tumor vascularity, and show early, 
rapid and intense enhancement, followed by quick washout 
of contrast administered for imaging purposes (Figure 5). 
Prostate cancer, chronic prostatitis and normal prostatic 
tissue demonstrate different vascular properties facilitating 
differentiation via DCE imaging. Vascular changes 
demonstrated by DCE MRI are also more distinct in high-
grade disease and sequences can be particularly useful for 
cancers which are not apparent on T2W imaging. DCE 
has shown high sensitivity and specificity in delineating 
malignant versus benign prostatic tissue with improved 
tumor localization compared with T2 weighted imaging 
(31,32). However, there can be difficulties in distinguishing 
prostatitis from malignancy in the PZ, and between BPH 
and malignancies in the transition zone (TZ) with this 
Figure 4 Utilizing diffusion weighted-imaging. (A) long b axial image, hyperintense tumour lesion right posterolateral zone, (B) hypointense 
lesion on ADC image.
Figure 5 Reduced enhancement of left posterior peripheral zone 
on DCE, concerning for T4 disease.
BA
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modality. 
Scoring systems for prostate MRI
Although MRI has been shown to be a powerful tool 
in the assessment and diagnosis of prostate cancer, one 
of the significant drawbacks is inter-rater variability. 
Standardization of prostate MRI reporting has been 
attempted using various scoring systems.
PI-RADS
To facilitate standardization in the reporting of prostate 
MRI, the European Society of Urogenital Radiology 
(ESUR) developed the Prostate Imaging and Report and 
Data System (PI-RADS v1) scoring system, published in 
2012 (33). This formalized MRI reporting though lacked 
guidance on production of an overall score thus resulting in 
heterogeneity in reporting. It was subsequently updated to 
PI-RADS v2 in 2014 by the PI-RADS Steering Committee. 
PI-RADS v2 is designed to improve the detection, 
localization, characterization and risk stratification in 
patients with suspected cancer in treatment naive prostate 
glands (27,34). 
PI-RADS v2 assessment uses a 5-point scale based on 
the likelihood that a combination of MP-MRI findings on 
T2W, DWI, and DCE correlates with the presence of a 
clinically significant cancer for each lesion in the prostate 
gland (Table 2). 
Compared to PI-RADS v1, the updated scoring system 
introduced the principle of a dominant sequence, according 
to which zone of the prostate was being assessed. For the 
peripheral zone, DWI is considered the dominant sequence, 
and T2WI for the TZ. DCE is employed in PZ imaging 
when DWI results are equivocal. Further inter-reader 
standardization is ensured with an algorithm based on the 
individual sequence and zone scores, allowing an overall 
score from 1 to 5 to be given in the final report. Head to 
head comparisons of PI-RADS v1 and PI-RADS v2 have 
shown mixed results. Overall, PI-RADS v2 appears to have 
greater diagnostic accuracy for TZ lesions, whereas PZ 
lesions are better evaluated with PI-RADS v1 (35). 
Likert scale
The Likert scale is a visual analogue scale, where scores 
of 1–5 represent the likelihood of cancer based on the 
radiologist’s overall interpretation of a prostate MRI scan (36). 
It does not require individual scoring assessment of separate 
sequences but an overall impression made by the radiologist. 
Scores of 1 and 2 represent a low suspicion of cancer, a score 
of 3 is equivocal, and a score of 4 or 5 is considered a high 
suspicion. Some studies have shown a good correlation with 
Likert scoring in detecting clinically significant cancers (37). 
Compared to PI-RADS v1, there appears to be good inter-
reader reproducibility in the PZ. However, in the TZ, 
the Likert scale performed better (38). The Likert scale 
scoring system does lack reproducibility outside of expert 
radiologist hands, requiring training to improve diagnostic 
accuracy (38).
Evidence for MP-MRI as a triage test
The ability of MP-MRI to rule-out clinically significant 
disease and allow men to safely avoid a biopsy is measured 
using the negative predictive value (NPV). Early 
retrospective studies found a wide variation in diagnostic 
accuracy with NPV ranging from 58–95% (39). This 
has been addressed in the recent PROstate MR Imaging 
Study (PROMIS) which assessed the ability of MP-MRI to 
identify men who can safely avoid unnecessary biopsy (40). 
MP-MRI was shown to have excellent performance 
characteristics with a sensitivity of 93% (95% CI, 88–96%) 
and NPV of 89% (95% CI, 93–94%). If introduced as a 
Table 2 PI-RADS v2 assessment categories
Score Description of scores
PIRADS 1 Very low (clinically significant cancer is highly unlikely to be present)
PIRADS 2 Low (clinically significant cancer is unlikely to be present)
PIRADS 3 Intermediate (the presence of clinically significant cancer is equivocal)
PIRADS 4 High (clinically significant cancer is likely to be present)
PIRADS 5 Very high (clinically significant cancer is highly likely to be present)
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triage test it was estimated that it would lead to a 27% 
reduction in men requiring a prostate biopsy. The study was 
multi-center and these performance characteristics were 
reproducible across a range of centers and radiologists. All 
MRIs were performed on 1.5 Tesla scanners without an 
endorectal coil, which was chosen due to it wide availability 
across all centers.
When considering whether MP-MRI can be used as a 
triage test, it is useful to compare to TRUS biopsy which 
has been the gold standard test over the last two decades. In 
PROMIS, TRUS biopsy was confirmed to be an inaccurate 
test with a sensitivity of 48% and NPV of 74% (95% CI, 
69–78) (40). The risk of missing disease is significantly 
higher with a TRUS biopsy as it is blind to the location 
of the cancer. In addition, TRUS-biopsy is associated 
with significant morbidity and over diagnosis of clinically 
insignificant disease due the random nature of the biopsy 
technique.
Benign features on MRI
BPH
BPH nodules are seen as encapsulated round nodules with 
circumscribed margins. If they are predominantly glandular, 
they show T2 hyperintensity, whereas stromal nodules show 
T2 hypointensity. On DWI they can show a range of signal 
intensities, and may be highly vascular on DCE.
BPH typically occurs in the TZ with formation of large, 
discrete, encapsulated nodules formed by the hyperplasia of 
stromal and epithelial cells (Figure 6). 
On T2-weighted imaging BPH results in a heterogeneous 
appearance which may be hypo-intense, iso-intense or 
hyper-intense according to the ratio of glandular to stromal 
tissue (41). Appreciation of the different BPH subtypes 
is critical in identification of malignant lesions (42). 
Glandular, cystic tissue responsible for prostatic secretions 
shows as high signal intensity on T2 weighted images and 
can be differentiated from neoplastic lesions owing to the 
different tissue properties. Conversely, mixed or sclerotic 
BPH nodules are composed of sclerotic, fibrous or muscular 
tissue resulting in hypo-intense lesions that can mimic 
neoplastic lesions within the TZ (Figure 7).
Stromal nodules also result in reduced signal intensity on 
DWI and early enhancement on DCE imaging, similar to 
cancerous tissue (43) (Figure 8).
In some cases, BPH may be found in PZ tissue and 
resemble prostate cancer. Well-defined, rounded lesions 
with internal heterogeneity on T2 weighted MRI are 
suggestive of benign hyperplasia over cancer.
Hemorrhage
Prostatic hemorrhage, commonly seen after biopsy, usually 
presents in the PZ. Cancerous tissue has a lower rate of 
hemorrhage than normal prostatic tissue as it has reduced 
levels of citrate, acting as an anti-coagulant and promoting 
resolution of hemorrhage faster than in the normal tissue (44). 
It is therefore possible that areas of prostate devoid of 
hemorrhage post-biopsy may be sites with positive biopsy 
Figure 6 BPH with stromal nodules.
Figure 7 Nodular hyperplasia of TZ with low probability of 
significant tumour.
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findings (Figure 9). 
The relationship between time and post-biopsy prostatic 
hemorrhage has led to the recommendation of an interval 
of at least six weeks and ideally 3 months between biopsy 
and imaging (27). 
Bleeding results in variably low signal intensity on T2 
weighted MRI depending on the time since biopsy whereas 
hemorrhage will be hyper-intense on T1 imaging. The 
high signal found on T1 MRI can limit the interpretation 
and yield of DCE studies with reduced differentiation 
between the high signal from areas of hemorrhage and 
enhancing malignant tissue. The variability in time since 
biopsy and signal intensity on MRI is also demonstrated 
on DWI although prostate cancer will result in a lower 
ADC compared to hemorrhage. Comparison of areas of 
hyper-intensity on T2 and DWI MRI with T1 weighted 
images allows application of the “hemorrhage exclusion 
sign”, facilitating delineation between lesions that are 
hemorrhagic in nature or cancerous in nature (44). Presence 
of the hemorrhage exclusion sign on T1 images (reduced 
signal intensity) and corresponding hypo-intensity on 
T2W imaging has shown a positive predictive value of 
approximately 95% for prostate cancer lesions (23).
Cysts 
Simple prostatic cysts will usually appear hyper-intense 
on T2W and hypo-intense on T1W, but may also show 
T1W hyper-intensity if they contain blood products or 
proteinaceous fluids (45) (Figure 10).
Following pelvic lymphadenectomy, lymphoceles may 
form along lymph node chains in the pelvic and para-aortic 
regions. Like simple prostatic cysts, these too demonstrated 
hypo-intensity on T1 weighted images and high-intensity 
on T2 images. Following administration of gadolinium 
contrast IV they do not enhance. Anatomical location is 
also useful in delineating such lesions from prostate cancer 
as they are located along lymph node chains dissected at 
the time of surgery whereas structural defects are identified 
nearby the tissue of origin, as with urethral diverticula 
(Figure 11).
Figure 8 Similarities between stromal nodules and tumour tissue. (A) T2 hypointensity at right apex; (B) hyperintensity of same lesion on 
DCE, likely tumour.
A B
Figure 9 Post-biopsy prostatic haemorrhage.
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Prostatitis
Prostatitis results in the formation of an immune infiltrate, 
the character of which depends on the cause of the 
inflammation (45). It demonstrates a diffuse, band-like, 
wedge-shaped morphology that may distinguish it from 
prostate cancer lesions which are more commonly round, 
oval or irregular and have a more focal decrease in signal 
attenuation on ADC mapping (Figure 12). 
However, extensive granulomatous prostatitis, for 
example secondary to BCG administration in bladder 
cancer therapy, may result in extra-capsular extension of 
the inflammation which can be more difficult to distinguish 
form malignant lesions (46,47).
With regards to imaging modalities, granulomatous 
prostatitis can manifest similarly to cancer with low signal 
intensity on T2 MRI, irregular margins and variable 
morphology found in the PZ (48). Reduction in T2 signal 
intensity may be secondary to calcification, fibrosis, or 
non-caseating necrosis. ADC is also reduced secondary to 
high cellular density. Areas of inflammation may increase 
perfusion on DCE sequences giving rise to a false-positive 
finding. However, DCE enhancement secondary to 
prostatitis is usually not as marked as found in prostate 
cancer.
Converse to non-specific granulomatous prostatitis, 
necrotizing granulomatous prostatitis results in necrosis 
with increased signal intensity on T2 imaging, marked 
hyper-intensity on ADC mapping secondary to increased 
diffusion restriction and non-enhancing lesions on DCE 
MRI.
Atrophy
Prostatic atrophy results from inflammation, chronic 
ischemia and exposure to radiation or anti-androgens. 
Microscopically, prostatic atrophy demonstrates crowded 
glands, scant cytoplasm and crowded nuclei when compared 
to prostatic tissue. There exist several sub-types including 
simple, sclerotic with cysts and post-atrophic hyperplasia. 
The glandular crowding present in the latter with complex 
glandular architecture can frequently be mistaken as 
malignant. In addition, there exists a positive correlation 
between the extent of prostatic atrophy and PSA elevation 
Figure 10 17 mm cystic lesion at right peripheral zone apex.
Figure 11 Crescent-shaped urethral diverticulum surrounding 
membranous urethra.
Figure 12 Prostatitis identified on MRI.
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likely released from damaged prostatic tissue (49).
On imaging, focal atrophy is more commonly located in 
the PZ with low signal intensity on T2 weighted imaging, 
moderate enhancement on DCE MRI and moderate 
restriction of diffusion in DWI (Figure 13). 
The lower rate of diffusion and reduced signal intensity 
is not as evident as that of cancerous lesions and is usually 
accompanied by loss of tissue volume. DWI and DCE 
images have been reported to result in a higher diagnostic 
yield in cases of prostatic atrophy and T2 MRI, more so 
than for other benign prostatic lesions (50).
Fibrosis
Fibrosis following inflammation or post-operative fibrosis 
results in wedge-shaped or band-shaped areas of hypo-
intensity on all MRI sequence modalities (45,51) (Figure 14).
Quantitative MRI
Advances in MRI techniques have facilitated increased 
sensitivity of prostate cancer detection and prediction of 
Gleason score. However, interpretation can be limited by 
the vast amounts of data amassed for each patient from 
each sequencing modality. Standardization is crucial in 
reducing inter-rater reliability and the accuracy of diagnosis 
of benign or malignant lesions. Computer aided diagnosis 
(CAD) utilizes software to aid radiologists in detecting 
and diagnosing abnormalities from diagnostic imaging. 
One such example is the quantitative analysis of diffusion 
properties within prostatic tissue through measurement 
of the ADC in DWI MRI (52). As demonstrated above, 
this imaging technology is currently limited by reliance on 
the underlying tissue microstructure and is not specific to 
histological features found in cancerous masses compared to 
benign tissue. 
New techniques of quantitative MRI use tissue-specific 
factors to delineate different cellular and microstructural 
phenotypes. VERDICT MRI (vascular, extracellular and 
restricted diffusion for cytometry in tumors) is a technique 
that maps the histological features of tissues by combining 
DWI with a mathematical model to provide information on 
cell size, density, extracellular-extravascular space volume 
fraction and vascularity via pseudo-diffusion coefficient 
associated with blood flow. It utilizes three main components 
to produce this information; vascular, extracellular-
extravascular space and intracellular water. These factors 
influence the DWI signal produced and by application to 
different diffusion times and weightings provides a more 
effective delineation of tissue microstructure than ADC 
from DWI MRI. In contrast to conventional histology 
of tissue samples, VERDICT MRI can characterize the 
micro-structure of a whole tumor enabling more reliable 
information surrounding its properties and likelihood of 
possessing cancerous properties.
Panagiotaki et al.  demonstrated its effectiveness 
through analysis of colorectal carcinoma xenografts where 
VERDICT MRI was able to characterize tumor type, 
Figure 13 Prostatic atrophy in peripheral zone on T2-MRI. Figure 14 T2 image with medial-mid right peripheral zone 
wedge-shaped hypodensity suggestive of fibrosis. Incidental 
midline Mullerian duct remnant.
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distinguish the microstructure of tumor histology and 
confirm tissue response to gemcitabine chemotherapy (53). 
On application to prostate cancer the technique was able 
to demonstrate increased intracellular and vascular volume 
fraction in cancerous compared to benign peripheral zone 
tissue which correlated with findings from histological 
specimens (P=0.05) (54). ADC and Kurtosis parameters 
were also able to distinguish benign from cancerous tissues 
though with less specific information than VERDICT.
MP-MRI and tumor volume
A MP-MRI derived tumor volume can be calculated 
using via manual measurements or 3-dimensional analysis 
software. The volume of the index lesion is a well-
established histological prognostic factor and traditionally 
set at 0.5 cc as described in the previous section of this 
article. The level of accuracy of MP-MRI volumetry 
remains under debate although the majority of studies have 
concluded that MP-MRI provides a reasonable estimation 
compared to volume on whole mount histology (55). The 
accuracy is greater for tumors over 10mm in diameter and 
larger than 0.5 cc in volume (56). MP-MRI does tend to 
systematically underestimate tumor volume and multiple 
studies have shown that the tumor extends beyond the 
boundaries of the visible portion of tumor on MRI (57). For 
this reason, when using MP-MRI to guide focal therapy 
rather than aiming to ablate the visible MRI tumor an 
additional safety margin should be defined (58).
Functional imaging 
There are a number of functional imaging methods which 
determine the metabolic activity of prostatic tissue (59). 
Molecular imaging refers to measuring biological processes 
to visualize and characterize tissues at both molecular and 
cellular levels. These techniques tend to have lower spatial 
resolution and the ability to image physiological processes 
provides valuable diagnostic information. 
MR spectroscopy
Proton MR spectroscopic imaging (MRSI) is a more 
technically challenging imaging modality than DCE 
and DWI MRI especially in the processing of images to 
create an acceptable output. This can be attributed to 
metabolites (citrate, creatinine, polyamines, and choline-
containing compounds) being of low signal intensity and 
the surrounding tissues being relatively lipid-rich (60). 
As previously mentioned, the presence of citrate in 
malignant tissue can aid differentiation from benign masses 
and MRSI utilizes the ratio of choline plus creatinine to 
citrate (CC/C) as a marker of cancer tissue. Studies have 
demonstrated the effectiveness of this as a marker of 
identifying cancer versus non-cancer in both the peripheral 
and central gland (61). Differences between median values 
of CC/C were observed between centers participating in 
the study. This finding may be attributed to heterogeneity 
in histopathologic information or size of cancer foci. 
Fusco et al.  found significant differences between 
clinically significant and insignificant prostate cancer 
on MR spectroscopy thus increasing the sensitivity and 
specificity in correlating with prostate biopsy results (62). 
Furthermore their study demonstrated disparities using 
different molecular markers but that optimum outcomes 
were achieved when combining the parameters of perfusion, 
diffusion and metabolism. However, other studies have 
failed to replicate such findings and have found that benign 
disease, such as chronic prostatitis, produced images 
that were indistinguishable from prostate cancer (63). 
Careful selection of metabolites and their ratios for analysis 
can facilitate comparison between different fields and 
acquisition schemes or automation of post-processing has 
potential to increase the reliability of ratio maps obtained 
to facilitate clinical utility (60).
Choline and prostate-specific membrane antigen 
(PSMA) positron emission tomography (PET)
An emerging image modality is PET with prostate cancer-
specific tracers. Over the last decade, this technique 
has developed as a better diagnostic tool for staging 
than conventional imaging. The conventional staging 
techniques involve bone scan for metastatic disease and 
nodal staging using CT or MRI which relies on changes to 
the morphology or size of lymph nodes. A meta-analysis 
of CT and MRI shows that these conventional techniques 
have a poor sensitivity of 39–42% and specificity of 82% 
for accurate lymph node staging (64).
In other tumor groups, the most common PET/CT 
tracer is 18F-FDG as a measurement of glycolytic activity 
of cells but in the context of prostate cancer it has not 
been effective (65). Localized prostate cancer tends to 
have low metabolic glycolytic activity compared to other 
cancers. FDG is also taken up by BPH nodules and the 
renal excretion of FDG means the high concentration in 
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the bladder can mask prostate tumors. Instead, choline-
based tracers have been introduced which detect the higher 
rate of lipid metabolism in prostate cancer cells. However 
due to their limited sensitivity, the current guidelines do 
not recommend using them for lymph node staging (66). 
Evangelista et al. completed a meta-analysis on the diagnostic 
accuracy of choline-based tracers showing a sensitivity of 
39.2% and specificity of 95% for lymph node detection (67). 
Following the limitations of choline and FDG-tracers, 
there is a need for tracers with improved accuracy. PSMA 
is showing significant potential. PSMA is a transmembrane 
protein with a 707-amino-acid extra cellular portion which 
is expressed in the apical region and epithelium around 
prostatic ducts (68). Despite being expressed in healthy 
prostate tissue, it’s overexpression on the cell membrane 
of prostate cancer cells makes it a promising target for 
functional imaging (69). PSMA is involved in the cellular 
uptake of folate which makes it a growth factor to malignant 
cells. Therefore, there are high levels of PSMA expression 
in metabolically active cells. As such, it is a marker of disease 
activity and is increased for higher Gleason scores (70). 
There is a growing body of evidence supporting the use of 
PSMA in primary staging. A meta-analysis including 1,309 
patients reported a sensitivity and specificity of 86% across 
sixteen articles involving 1,309 patients. 
Hyperpolarized MRI
Hyperpolarization refers to the ex vivo application of 
increased spin polarization to small molecules and then 
administration with MRI to allow the visualization of the 
molecule’s metabolism in vivo. The increased polarization 
increases the signal produced by up to 10,000 times compared 
to that which is produced by physiological concentrations of 
the molecule on standard MRI (71). 13C-pyruvate has been 
employed for this technology, via microwave irradiation 
through transfer of hyperpolarized electrons. 
Nelson et al. first demonstrated the feasibility and safety 
of hyperpolarized MRI in men with prostate cancer on active 
surveillance (72). They demonstrated increased signal intensity 
in areas of the prostate that included tumor and low or 
undetectable signal from normal prostatic tissue which converts 
four to five times less pyruvate to lactate than malignant tissue. 
The technique was able to delineate regions of biopsy-proven 
tumor that had not been located during staging examination 
by MP-MRI, demonstrating the potential for hyperpolarized 
MRI to increase diagnostic yield and differentiate high-grade, 
low-grade and benign tissue. Additionally, the same group was 
able to illustrate the technique’s effectiveness as a biomarker of 
response to androgen deprivation therapy where T2 weighted 
imaging and ADC had limited change between pre-treatment 
and post-treatment imaging. This response correlated with 
clinical response to therapy where the patient reached a PSA 
nadir after six months (73).
While hyperpolarized MRI shows promise in improving 
the imaging and differentiation of benign and malignant 
lesions, there is work to be done before recommending 
more widespread use (74). For example, for its application 
there is  a need to identify suitable molecules for 
hyperpolarization through analysis of metabolic pathways 
within tumor tissue and cancer-specific biomarkers. 
Technology for storage of hyperpolarized molecules 
and protocols for quality assurance, reproducibility and 
reduction of inter-rater variability needs investment and 
larger, more wide-spread studies are necessary.
Discussion
Discrimination between benign and malignant lesions 
on imaging is an important element in identification of 
patients who require invasive investigations and potentially 
treatment for prostate cancer. Current reliance on TRUS-
guided biopsy subjects patients to an uncomfortable 
procedure which has associated risks and has been linked 
with the over-diagnosis and over-treatment of low-grade 
disease and oversight of more concerning, aggressive 
disease (75). Several MRI techniques have evolved that can 
aid radiologists, clinicians and surgeons in evaluating prostatic 
lesions, notably quantitative MRI and functional imaging. 
However benign condition such as BPH, hemorrhage, cysts, 
prostatitis, atrophy, and fibrosis can occasionally mimic cancer 
and more novel techniques show promise in furthering the 
ability to discern between benign and malignant disease.
Thus, appearance of abnormalities on MRI is not the 
only parameter to be borne in mind particularly when 
trying to distinguish which patients need a biopsy. Muthigi 
et al. found a lower PSA, higher prostate volume, and fewer 
targeted cores were seen to be predictors of upgrading on 
systematic biopsy when compared to those patients who 
underwent biopsies targeted only at a MRI lesion (76).
There is evidence to suggest that the negative predictive 
value in patients with a negative MRI and a PSA density of 
≤0.2 ng/mL is 0.91 for the detection of Gleason score ≥7 
prostate cancer and thus these patients could safely avoid 
biopsy (77). Conversely, those with a PSA density of ≥0.2 
and a negative or equivocal MRI should undergo biopsy as 
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they may harbor clinically significant disease (NPV 0.71) 
(78,79). Others such as Venderink et al. have reported on 
a PSA density threshold of 0.15 ng/mL as the cut-off for 
biopsy in patients with a PIRADS 3 lesion. They found 
that utilizing this threshold would have avoided biopsy in 
42% of patients with a PIRADS 3 lesion, whilst only 6% of 
clinically significant cancer would have been missed (80). 
Similarly promising results were obtained by Rayn et 
al. when examining findings from MP-MRI with existing 
staging nomograms that incorporate PSA, Gleason Grade 
Group and clinical staging. The study found that smaller 
lesion diameter on MP-MRI was the strongest predictor 
for organ-confined disease and for non-organ confined 
disease the MP-MRI findings had greater predictive 
value than Partin and Memorial Sloan Kettering Cancer 
Centre nomograms alone. Addition of MP-MRI to staging 
nomograms significantly improves prediction of organ-
confined disease, extraprostatic extension and seminal 
vesicle invasion increasing the predictive ability of adverse 
features at the time of radical prostatectomy.
Emergence of biomarkers may also change the diagnostic 
landscape allowing stratification of patients alongside a 
MRI with tests such as PHI showing promise, however 
significant research in this his field is needed prior to their 
widespread utilization (81). 
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